Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 28 July 1989:
Vol. 245. no. 4916, pp. 412 - 415
DOI: 10.1126/science.2502840
Prev | Table of Contents | Next

Articles

Science, Vol 245, Issue 4916, 412-415
Copyright © 1989 by American Association for the Advancement of Science

articles

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

R Yarchoan, H Mitsuya, RV Thomas, JM Pluda, NR Hartman, CF Perno, KS Marczyk, JP Allain, DG Johns, and S Broder

Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892.

The purine analog 2',3'-dideoxyinosine (ddI), which has anti-retroviral activity in vitro was administered for up to 42 weeks to 26 patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex (ARC). Ten of these individuals were AZT-intolerant. Eight dose regimens were studied. The drug was orally bioavailable and penetrated into the cerebrospinal fluid (CSF). Comparatively little evidence of an effect against human immunodeficiency virus (HIV) was seen at the lowest four doses. However, patients in the four highest dose groups (ddI at 1.6 milligrams per kilogram intravenously and then greater than or equal to 3.2 milligrams per kilogram orally at least every 12 hours or higher) had increases in their circulating CD4+ T cells (P less than 0.0005), increased CD4/CD8 T cell ratios (P less than 0.01), and, where evaluable, more than an 80% decrease in serum HIV p24 antigen (P less than 0.05). The patients also had evidence of improved immunologic function, had reduced viremic symptomatology, and gained a mean of 1.6 kilogram with these comparatively infrequent dosing schedules (every 8 or 12 hours). The most notable adverse effects directly attributable to ddI administration at the doses used in this study included increases in serum uric acid (due to hypoxanthine release) and mild headaches and insomnia. These results suggest that serious short-term toxicity at therapeutic doses is not an inherent feature in the profile of agents with clinical anti-HIV activity. Further controlled studies to define the safety and efficacy of this agent may be worth considering.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Molecular Modeling Approach to Understanding the Mode of Action of L-Nucleosides as Antiviral Agents.
K. Lee and C. K. Chu (2001)
Antimicrob. Agents Chemother. 45, 138-144
   Abstract »    Full Text »
Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within the gag-pol Transframe Domain.
S. Sei, Q.-e. Yang, D. O'Neill, K. Yoshimura, K. Nagashima, and H. Mitsuya (2000)
J. Virol. 74, 4621-4633
   Abstract »    Full Text »
Quantitation of Intracellular Triphosphate of Emtricitabine in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients.
A. Darque, G. Valette, F. Rousseau, L. H. Wang, J.-P. Sommadossi, and X.-J. Zhou (1999)
Antimicrob. Agents Chemother. 43, 2245-2250
   Abstract »    Full Text »
Activated Memory CD4+ T Helper Cells Repopulate the Intestine Early following Antiretroviral Therapy of Simian Immunodeficiency Virus-Infected Rhesus Macaques but Exhibit a Decreased Potential To Produce Interleukin-2.
J. J. Mattapallil, Z. Smit-McBride, P. Dailey, and S. Dandekar (1999)
J. Virol. 73, 6661-6669
   Abstract »    Full Text »
Intracellular Nucleotides of (-)-2',3'-Deoxy-3'-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus.
C. Solas, Y.-F. Li, M.-Y. Xie, J.-P. Sommadossi, and X.-J. Zhou (1998)
Antimicrob. Agents Chemother. 42, 2989-2995
   Abstract »    Full Text »
Dicaffeoylquinic and Dicaffeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase.
B. McDougall, P. J. King, B. W. Wu, Z. Hostomsky, M. G. Reinecke, and W. E. Robinson Jr. (1998)
Antimicrob. Agents Chemother. 42, 140-146
   Abstract »    Full Text »
Identification of the Metabolites of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine in Monkeys.
M. Chang, V. K. Sood, D. A. Kloosterman, M. J. Hauer, P. E. Fagerness, P. E. Sanders, and J. J. Vrbanac (1997)
Drug Metab. Dispos. 25, 814-827
   Abstract »    Full Text »
Metabolism of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine In Mice.
M. Chang, V. K. Sood, G. J. Wilson, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, W. Zhang, and D. G. Branstetter (1997)
Drug Metab. Dispos. 25, 828-839
   Abstract »    Full Text »
Decay Rates of Anti-HIV Dideoxynucleotides in Tissue Culture Systems: A Simple Correction for the Effect of Cell Replication.
G. S. Ahluwalia, R. L. Dedrick, J. S. Driscoll, P. F. Morrison, W.-Y. Gao, and D. G. Johns (1997)
Drug Metab. Dispos. 25, 893-0
   Abstract »    Full Text »
Metabolism of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Delavirdine in Rats.
M. Chang, V. K. Sood, G. J. Wilson, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, and P. E. Fagerness (1997)
Drug Metab. Dispos. 25, 228-242
   Abstract »    Full Text »
Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter.
L. D. Saravolatz, D. L. Winslow, G. Collins, J. S. Hodges, C. Pettinelli, D. S. Stein, N. Markowitz, R. Reves, M. O. Loveless, L. Crane, et al. (1996)
N. Engl. J. Med. 335, 1099-1106
   Abstract »    Full Text »    PDF »
Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine.
R. Dolin, D. A. Amato, M. A. Fischl, C. Pettinelli, M. Beltangady, S.-h. Liou, M. J. Brown, A. P. Cross, M. S. Hirsch, W. D. Hardy, et al. (1995)
Arch Intern Med 155, 961-974
   Abstract »    PDF »
Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection -- A Preliminary Study.
J. A. Kovacs, M. Baseler, R. J. Dewar, S. Vogel, R. T. Davey, J. Falloon, M. A. Polis, R. E. Walker, R. Stevens, N. P. Salzman, et al. (1995)
N. Engl. J. Med. 332, 567-575
   Abstract »    Full Text »    PDF »
A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection.
D. I. Abrams, A. I. Goldman, C. Launer, J. A. Korvick, J. D. Neaton, L. R. Crane, M. Grodesky, S. Wakefield, K. Muth, S. Kornegay, et al. (1994)
N. Engl. J. Med. 330, 657-662
   Abstract »    Full Text »
A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase.
M. S. Saag, E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, et al. (1993)
N. Engl. J. Med. 329, 1065-1072
   Abstract »    Full Text »
Therapy for Human Immunodeficiency Virus Infection.
M. S. Hirsch and R. T. D'Aquila (1993)
N. Engl. J. Med. 328, 1686-1695
   Full Text »
Present status and future prospects for HIV therapies.
M. Johnston and D. Hoth (1993)
Science 260, 1286-1293
   Abstract »    PDF »
Zidovudine: Five Years Later.
G. X. McLeod and S. M. Hammer (1992)
Ann Intern Med 117, 487-501
   Abstract »    PDF »
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
M. St Clair, J. Martin, G Tudor-Williams, M. Bach, C. Vavro, D. King, P Kellam, S. Kemp, and B. Larder (1991)
Science 253, 1557-1559
   Abstract »    PDF »
Fulminant Hepatic Failure Associated with 2',3'-Dideoxyinosine (ddI).
K. K. Lai, D. L. Gang, J. K. Zawacki, and T. P. Cooley (1991)
Ann Intern Med 115, 283-284
   Abstract »    PDF »
Antiretroviral Therapy in AIDS.
S. Broder, H. Mitsuya, R. Yarchoan, and G. N. Pavlakis (1990)
Ann Intern Med 113, 604-618
   Abstract »    PDF »
Molecular targets for AIDS therapy.
H Mitsuya, R Yarchoan, and S Broder (1990)
Science 249, 1533-1544
   Abstract »    PDF »
Infectious Diseases.
R. G. Douglas Jr (1990)
JAMA 263, 2648-2649
   Abstract »    PDF »
The AIDS Litigation Project: A National Review of Court and Human Rights Commission Decisions, Part I: The Social Impact of AIDS.
L. O. Gostin (1990)
JAMA 263, 1961-1970
   Abstract »    PDF »
Trials and tribulations of AIDS drug testing.
J Palca (1990)
Science 247, 1406
   PDF »
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells.
Q. Meng, D. M. Walker, O. A. Olivero, X. Shi, B. B. Antiochos, M. C. Poirier, and V. E. Walker (2000)
PNAS 97, 12667-12671
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)